Alto Neuroscience Receives $11.7M Funding Award From Wellcome Trust To Accelerate Development Of ALTO-100 In Bipolar Depression Leveraging Precision Psychiatry Approach
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience (NYSE:ANRO) has received an $11.7 million funding award from the Wellcome Trust to advance the development of ALTO-100 in bipolar depression. The funding will support a Phase 2b study involving 200 patients, leveraging a cognitive biomarker approach. Topline data is expected in 2026.
July 25, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alto Neuroscience has received $11.7 million from the Wellcome Trust to advance ALTO-100 in bipolar depression. This funding will support a Phase 2b study, with topline data expected in 2026.
The $11.7 million funding from the Wellcome Trust is a significant boost for Alto Neuroscience, enabling the advancement of their lead candidate ALTO-100 in a critical Phase 2b study. This could potentially lead to positive clinical outcomes and future revenue streams, positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100